KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)

Authors :: Georgia Chenevix-Trench
Paul D.P. Pharoah
F.H. van der Baan
Matti A. Rookus
Andrew Berchuck
Ellen L. Goode
Sharon E. Johnatty
Source :: Gynecologic Oncology. 137:26-27
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Internal medicine
medicine
Cancer research
Obstetrics and Gynecology
KRAS
business
Ovarian cancer
medicine.disease
medicine.disease_cause

Tools